Ingestion of a blue dye tablet during bowel prep for colonoscopy could be a significant advance in the early detection of colorectal cancer (CRC). When used in conjunction with colonoscopy, the blue dye increased adenoma detection rate (ADR) by nearly 9 percent, according to a study scheduled for presentation at Digestive Disease Week® (DDW) 2018.
Increasingly, liver transplant centers are changing a long-standing practice of delaying potentially life-saving liver transplantation for patients with severe alcoholic hepatitis until after they stopped drinking alcohol for six months, according to a new study scheduled for presentation at Digestive Disease Week® (DDW) 2018.
Combining a DNA vaccine, which boosts the body's immune response against tumors, with an antibody that blocks the body's natural defense against the potency of the DNA vaccine, may lead to the development of an effective treatment for late stage colorectal cancer, when a cure is not often possible. Preliminary research leading up to this trial will be presented at Digestive Disease Week® 2018.
An investigational new drug offers hope of relief for celiac disease patients who are inadvertently exposed to gluten while on a gluten-free diet. Findings of the first phase 2 study of a biologic immune modulator in celiac disease will be presented at the upcoming Digestive Disease Week® (DDW) 2018. Inadvertent exposure to gluten can be a frequent occurrence for celiac patients that triggers symptoms, such as pain in the gut and diarrhea, due to intestinal damage.
Macrophages are white blood cells that perform different functions with different energy needs. M2-type macrophages have anti-inflammatory properties that may protect against inflammatory disorders such as inflammatory bowel disease (IBD). However, the molecular pathways driving M2 formation are not fully understood. Researchers identified a protein commonly involved in nervous system development that plays a key role in metabolism of M2 macrophages and protecting against colitis symptoms in mice. The findings may lead to new therapeutic targets for inflammatory diseases.
Researchers in Germany have discovered that colon cancers are often resistant to existing drug treatments because they are composed of two different cell types that can replace each other when one cell type is killed. The study, which will be published May 16 in the Journal of Experimental Medicine, suggests that combination therapies targeting both cell types at once may be more effective at treating colorectal cancer, the third highest cause of cancer-related death in the United States.
Researchers presenting at the 51st ESPGHAN Annual Meeting have today revealed the results of a new study which proves the efficacy and effectiveness of using ginger to treat vomiting in children with acute gastroenteritis -- one of the most common conditions resulting in admission to pediatric emergency departments.
An international research team has today reported the first results of a study investigating the natural history of progressive familial intrahepatic cholestasis (PFIC) -- a rare genetic liver disease that predominantly affects children. Most alarmingly, the team reported that, by the age of 10 years, approximately half of the children with two different forms of PFIC had already received a liver transplant.
Targeted probiotic supplementation in breastfed infants can significantly reduce the potential for antibiotic resistance, new research presented today at the 51st ESPGHAN Annual Meeting shows.
As the number of Americans with acid reflux grows, a study by researchers at the University of Colorado Anschutz Medical Campus says invasive procedures to treat those who don't respond to medication should be done for select patients.